Format

Send to

Choose Destination
Gynecol Oncol. 2005 Mar;96(3):902-5.

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.

Author information

1
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA.

Abstract

BACKGROUND:

Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.

CASE:

A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.

CONCLUSION:

Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.

PMID:
15721449
DOI:
10.1016/j.ygyno.2004.12.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center